Bjorner JB, Larsen S, Lubker C, Holst-Hansen T, et al. The improved health utility of once-weekly subcutaneous semaglutide 2.4 mg compared with placebo in the STEP 1-4 obesity trials. Diabetes Obes Metab 2023;25:2142-2150.
PMID: 37055712